2026-04-17T20:41:46Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2190632025-12-04T19:08:34Zcom_2072_1057col_2072_478858col_2072_478917col_2072_478921

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir Ortiz Rodrigo, Alba Ríos, María Tobías, Ester Noguera Julian, Antoni García García, Francesc Josep Cantó Santos, Judith Valls-Roca, Laura Garrabou Tornos, Glòria Grau, Josep Maria Cardellach, Francesc Sánchez, Emilia Morén Núñez, Constanza Fortuny Guasch, Claudia Infants Infeccions per citomegalovirus Medicaments antivírics Children Cytomegalovirus infections Antiviral agents Background: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Similar anti-HIV drugs have been associated with mitochondrial toxicity but this has never been explored in CMV. Objective: To determine the potential mitochondrial toxicity profile at the genetic, functional and biogenesis level in peripheral blood mononuclear cells from a cohort of newborns and infants with symptomatic congenital CMV infection (treated with valganciclovir, untreated and uninfected controls). Design: Longitudinal, observational and controlled study. Setting and patients: Subjects were recruited at the tertiary referral Hospital Sant Joan de Déu and experiments were conducted at IDIBAPS-Hospital Clínic of Barcelona, Spain. CMV-infected newborns underwent comprehensive monthly clinical follow-up. Methods: Mitochondrial parameters, audiometry and neurological assessment were measured at baseline, 3-6 and 12 months after inclusion in the study. The Kruskal-Wallis test for k-independent samples and Friedman tests for repeated measurements were applied. Results: Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). Conclusions: No evidence of mitochondrial toxicity was found in infants treated with valganciclovir for congenital CMV. 2025-02-20T18:38:17Z 2025-02-20T18:38:17Z 2022-03-14 2025-02-20T18:38:18Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 0003-9888 https://hdl.handle.net/2445/219063 722724 35288419 eng Reproducció del document publicat a: https://doi.org/10.1136/archdischild-2021-322996 Archives of Disease in Childhood, 2022, vol. 107, num.7, p. 686-691 https://doi.org/10.1136/archdischild-2021-322996 cc-by-nc (c) Ortiz-Gracia, A. et al., 2022 http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess 6 p. application/pdf BMJ Publishing Group Articles publicats en revistes (Medicina)